Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS
    Ascentage Pharma Releases Updated Lisaftoclax Data in MDS

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharma-releases-updated-data-of-bcl-2-inhibitor-lisaftoclax-in-mds-that-demonstrates-potential-clinical-benefits-and-favorable-safety-302327621.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-in-combinations-demonstrates-potential-clinical-benefit-in-patients-with-prior-exposure-to-venetoclax-302327542.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China

    17 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-lisaftoclax-accepted-and-recommended-priority-review-designation-by-cde-of-china-nmpa-302307744.html

    PR NEWSWIRE
    17 Nov 2024
    Share Share
    ASH 2024: Ascentage Pharma's Lisaftoclax Data to Be Presented
    ASH 2024: Ascentage Pharma's Lisaftoclax Data to Be Presented

    06 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ash-2024--results-from-three-clinical-studies-of-ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-selected-for-presentations-including-an-oral-report-302297323.html

    PR NEWSWIRE
    06 Nov 2024
    Share Share
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis

    18 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-eha-2024--ascentage-pharma-releases-updated-data-of-lisaftoclax-in-patients-with-rr-mm-and-al-amyloidosis-highlighting-marked-improvement-in-orr-302175033.html

    PR NEWSWIRE
    18 Jun 2024
    Share Share
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-asco-2024--ascentage-pharma-releases-updated-data-showing-promising-efficacy-and-safety-of-lisaftoclax-in-patients-with-wm-302164161.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share